In addition, the SNHG14/miR-5590-3p/ZEB1 positive feedback loop was found to promote the progression and immune escape of DLBCL by regulating the PD-1/PD-L1 checkpoint, suggesting that targeting SNHG14 is a potential method of improving the efficacy of DLBCL immunotherapy (133). The gene discussed is SNHG14; the disease is diffuse large B-cell lymphoma.